Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change
15/06/26	0.1550 $	+6.90%
12/06/26	0.1450 $	-6.45%
11/06/26	0.1550 $	+3.33%
10/06/26	0.1500 $	0.00%
09/06/26	0.1500 $	0.00%

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1550CAD

Average target price

0.4500CAD

Spread / Average Target

+190.32%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Toronto S.E. Other stock markets 01:20:25 16/06/2026 HKT			5-day change	1st Jan Change
0.1550 ^CAD	+6.90%		+3.33%	+19.23%

06-12	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
04-23	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding	CI

Market Cap	58.53M 41.88M 36.09M 33.22M 31.16M 3.96B 59.12M 393M 153M 1.94B 157M 154M 6.71B	P/E Ratio 2026 *	-5.17x	P/E Ratio 2027 *	-3.88x
Enterprise Value	58.53M 41.88M 36.09M 33.22M 31.16M 3.96B 59.12M 393M 153M 1.94B 157M 154M 6.71B	EV / Sales 2026 *	-	EV / Sales 2027 *	11.7x
Free-Float	86.83%	Yield 2026 *	-	Yield 2027 *	-

06-12	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
04-23	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding	CI
03-14	Sernova Biotherapeutics Inc Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
03-05	Sernova Biotherapeutics Inc announced that it expects to receive CAD 7.1 million in funding	CI
12-20	Sernova Biotherapeutics Inc Reports Earnings Results for the Full Year Ended October 31, 2025	CI
12-19	Sernova Biotherapeutics Inc Auditor Raises 'Going Concern' Doubt	CI
11-13	Sernova Biotherapeutics Inc announced that it expects to receive CAD 5 million in funding	CI
23/09/25	Sernova Biotherapeutics Inc Appoints John L. Brooks III as Chair of the Board of Directors	CI
16/09/25	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025	CI
09/07/25	Sernova Partners With Eledon Pharmaceuticals to Advance Potential Functional Cure for Type 1 Diabetes	MT
09/07/25	Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance A Potential Functional Cure for Type 1 Diabetes	CI
14/06/25	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2025	CI
04/06/25	Sernova Biotherapeutics Announces Executive Changes	CI

04-24	Sernova Biotherapeutics Announces Closing of Recently Approved Financings	NE
04-09	Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders	NE
03-24	Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing	NE
03-16	Sernova Biotherapeutics : 2026 Q1 MD&A	PU
03-16	Sernova Biotherapeutics : 2026 Q1 Financial Statements	PU

Sernova Stock Toronto S.E.

Stocks

SVA

CA81732W1041

Medical Equipment, Supplies & Distribution

Valuation: Sernova

Chart: Sernova

Latest news : Sernova

Press Releases: Sernova

News in other languages: Sernova

Quotes and Performance

Course Extremes

Managers and Directors: Sernova

Medical Devices & Implants

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

15/09/23	Sernova-Telefonkonferenz für Investoren, die ursprünglich für den 15. September geplant war, wird nun auf den 22. September verschoben
13/09/23	Sernova veranstaltet Telefonkonferenzen für Investoren zur Vorstellung der neu ernannten CEO und zur Bekanntgabe eines Updates zur Geschäftsentwicklung
03/05/23	AstraZeneca : accord de recherche avec le canadien Sernova
03/05/23	Sernova kündigt Forschungskooperation mit dem Pharmakonzern AstraZeneca an, um neuartige potenzielle Zelltherapie-Anwendungen zu untersuchen
10/04/23	Sernova präsentiert beim 2023 Cell & Gene Meeting on the Med der Alliance for Regenerative Medicine

1 week	+3.33%
Current month	+10.71%
3 months	-8.82%
6 months	+10.71%
Current year	+19.23%

1 week	0.14	0.16
1 month	0.14	0.17
3 years	0.12	1.1
5 years	0.12	2.22
10 years	0.1	2.87

Manager	Title	Age	Since
Jonathan Rigby CEO	Chief Executive Officer	58	12/08/2024
James Parsons DFI	Director of Finance/CFO	60	11/10/2024
David Burke IRC	Investor Relations Contact	-	11/10/2024

Director	Title	Age	Since
Tanya Lewis BRD	Director/Board Member	55	-
John Brooks CHM	Chairman	75	23/09/2025
James Parsons BRD	Director/Board Member	60	19/04/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERNOVA	+6.90%	+3.33%	-6.06%	-81.98%	41.88M
STRYKER CORPORATION	-1.36%	+2.13%	-18.38%	+4.16%	118B
SMITH & NEPHEW PLC	+0.97%	-1.21%	+5.36%	-9.16%	12.9B
GLAUKOS CORPORATION	+2.63%	+6.71%	+33.34%	+92.83%	7.64B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-0.70%	-0.58%	-47.25%	-71.57%	4.17B
DOUBLE MEDICAL TECHNOLOGY INC.	+0.78%	+5.80%	+12.86%	+33.75%	2.57B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-0.61%	+11.08%	-16.28%	-15.78%	1.78B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-1.86%	-6.44%	+3.12%	-15.50%	1.63B
L&C BIO CO.,LTD	-0.91%	-8.41%	+150.66%	+121.83%	1.36B
Average	-0.15%	+2.13%	+13.04%	+6.51%	18.76B
Weighted average by Cap.	-0.90%	+2.10%	-12.19%	+6.52%

	2026 *	2027 *
Net sales	-	5M 3.58M 3.08M 2.84M 2.66M 338M 5.05M 33.54M 13.1M 166M 13.42M 13.14M 573M
Net income	-12.83M -9.18M -7.91M -7.28M -6.83M -867M -12.96M -86.05M -33.61M -425M -34.44M -33.71M -1.47B	-19.77M -14.14M -12.19M -11.22M -10.53M -1.34B -19.97M -133M -51.81M -655M -53.08M -51.96M -2.27B
Net Debt	-	-